FDA approved drugs repurposing of Toll-like receptor4 (TLR4) candidate for neuropathy

Document Type : Research article


1 Dpartment of Tissue Engineering and Applied Cell, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Proteomics Research Center, Faculty of paramedical science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Institute of Biochemistry and Biophysics, Tehran University, Tehran, Iran.

4 Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization, Karaj, Iran.

5 Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences,Tehran, Iran.


Accumulating evidence indicates that toll-like receptor 4 (TLR4) plays a critical role in promoting adaptive immune responses and are definitively involved in the expansion and maintenance of the neuropathic pain. However, the application of docking in virtual-screening in silico methods to drug discovery has some challenge but it allows us to make the directed and meaningful design of drugs for a target protein, which can be shortening and low costing the evolution and discovery of very promising lead new drugs. Nevertheless, in parallel with virtual screening methods, attendant developments in cell culture and in vivo studies must be achieved. In the present paper, we aimed to discover new drugs that have the ability to bind and inhibit TLR4 functions. So, after using the Pathway studio to investigate the biological pathways and protein interaction maps between TLR4 and neuropathy, we reported the application of the affinity-based approach of different pharmaceuticals; these agents contained all of the approved drugs; which could bind to Toll-like receptor 4 in blind high-throughput in silico screening. Our results demonstrated that among the primary list of 1945 retrieved compounds, 39 approved compounds could be the right candidate to perform a biological test in different in vivo and in vitro conditions and as a lead for further neurophysiological and neuropathological studies and treatment of neuropathic pain.


Main Subjects

Vaure C and Liu Y. A comparative review of toll-like

receptor 4 expression and functionality in different

animal species.
Front. Immunol. (2014) 5: 316.
Funami K, Matsumoto M, Oshiumi H, Inagaki F

and Seya T. Functional interfaces between TICAM-

2/TRAM and TICAM-1/TRIF in TLR4 signaling.

Biochem. Soc. Trans
. (2017) 45: 929-35.
Ellis A, Grace PM, Wieseler J, Favret J, Springer K,

Skarda B, Ayala M, Hutchinson MR, Falci S, Rice

KC, Maier SF and Watkins LR. Morphine amplifies

mechanical allodynia via TLR4 in a rat model of spinal

cord injury.
Brain Behav. Immun. (2016) 58: 348-56.
Grace PM, Maier SF and Watkins LR. Opioid-induced

central immune signaling: implications for opioid

Headache (2015) 55: 475-89.
Reichardt F, Chassaing B, Nezami BG, Li G,

Tabatabavakili S, Mwangi S, Uppal K, Liang B,

Vijay-Kumar M, Jones D, Gewirtz AT and Srinivasan

S. Western diet induces colonic nitrergic myenteric

neuropathy and dysmotility in mice via saturated

fatty acid- and lipopolysaccharide-induced TLR4

J. Physiol. (2017) 595: 1831-46.
Coquenlorge S, Duchalais E, Chevalier J, Cossais F,

Rolli-Derkinderen M and Neunlist M. Modulation

of lipopolysaccharide-induced neuronal response

by activation of the enteric nervous system.
. (2014) 11: 202.
Voss U and Ekblad E. Lipopolysaccharide-induced

loss of cultured rat myenteric neurons - role of AMP-

activated protein kinase.
PLoS One (2014) 9: e114044.
Beutler BA. TLRs and innate immunity.
Blood (2009)
113: 1399-407.

Li J, Yang F, Wei F and Ren X. The role of toll-like

receptor 4 in tumor microenvironment.
(2017) 8: 66656-67.

Bagheri B, Razavi S, Gohari A, Salarian S and Dabbagh

A. Toll-Like Receptor 4 in Ventilator-Induced Lung

Injuries: Mechanism of Disease.
J. Cell. Mol. Anesth.
(2016) 1: 34-9.

Zaal A, Nota B, Moore KS, Dieker M, van Ham

SM and Ten Brinke A. TLR4 and C5aR crosstalk in

dendritic cells induces a core regulatory network of

RSK2, PI3Kbeta, SGK1, and FOXO transcription

J. Leukoc. Biol. (2017) 102: 1035-54.
Talebi Z, Peyvandi H and Dabbagh A. Cellular and

molecular mechanisms in perioperative hepatic

protection: a review of current interventions.
J. Cell.
Mol. Anesth.
(2017) 2: 82-93.
Martín-Ávila A, Medina-Tamayo J, Ibarra-Sánchez A,

Vázquez-Victorio G, Castillo-Arellano J, Hernández-

Mondragón A, Rivera J, Madera-Salcedo IK, Blank

U, Macías-Silva M and González-Espinosa C. Protein

Tyrosine Kinase Fyn Regulates TLR4-Elicited













Zali H et al. / IJPR (2019), 18 (3): 1639-16471646
Responses on Mast Cells Controlling the Function

of a PP2A-PKCα/β Signaling Node Leading to TNF

J. Immunol. (2016) 196: 5075-88.
Qi X, Qin L, Du R, Chen Y, Lei M, Deng M and

Wang J. Lipopolysaccharide Upregulated Intestinal

Epithelial Cell Expression of Fn14 and Activation of

Fn14 Signaling Amplify Intestinal TLR4-Mediated

Front. Cell. Infect. Microbiol. (2017)
7: 315.

Garay-Malpartida HM, Mourao RF, Mantovani M,

Santos IA, Sogayar MC, and Goldberg AC. Toll-like

receptor 4 (TLR4) expression in human and murine

pancreatic beta-cells affects cell viability and insulin

BMC. Immunol. (2011) 12: 18.
Gerke V, Creutz CE and Moss SE. Annexins: linking

Ca2+ signalling to membrane dynamics.
Nat. Rev.
Mol. Cell. Biol.
(2005) 6: 449-61.
Jiang Z, Georgel P, Li C, Choe J, Crozat K, Rutschmann

S, Du X, Bigby T, Mudd S, Sovath S, Wilson IA, Olson

A and Beutler B. Details of Toll-like receptor:adapter

interaction revealed by germ-line mutagenesis.
Natl. Acad. Sci. U. S. A.
(2006) 103: 10961-6.
Li J, Csakai A, Jin J, Zhang F and Yin H. Therapeutic

developments dargeting Toll-like Receptor-4-dediated

ChemMedChem (2016) 11: 154-

Leow-Dyke S, Allen C, Denes A, Nilsson O, Maysami

S, Bowie AG, Rothwell NJ and Pinteaux E. Neuronal

Toll-like receptor 4 signaling induces brain endothelial

activation and neutrophil transmigration
in-vitro. J.
(2012) 9: 230.
Okun E, Griffioen KJ and Mattson MP. Toll-like

receptor signaling in neural plasticity and disease.

Trends. Neurosci
. (2011) 34: 269-81.
Gorina R, Font-Nieves M, Marquez-Kisinousky

L, Santalucia T and Planas AM. Astrocyte TLR4

activation induces a proinflammatory environment

through the interplay between MyD88-dependent

NFkappaB signaling, MAPK, and Jak1/Stat1

Glia (2011) 59: 242-55.
Bettoni I, Comelli F, Rossini C, Granucci F, Giagnoni

G, Peri F and Costa B. Glial TLR4 receptor as new

target to treat neuropathic pain: efficacy of a new

receptor antagonist in a model of peripheral nerve

injury in mice.
Glia (2008) 56: 1312-9.
Tanga FY, Nutile-McMenemy N and DeLeo JA.

The CNS role of Toll-like receptor 4 in innate

neuroimmunity and painful neuropathy.
Proc. Natl.
Acad. Sci. U. S. A.
(2005) 102: 5856-61.
Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning

CJ, Issels RD and Wagner H. HSP70 as endogenous

stimulus of the Toll/interleukin-1 receptor signal

J. Biol. Chem. (2002) 277: 5107-12.
Dabbagh A. Microglial Cells: the Bridge Between

the Immune System and Pain in the Central Nervous

J. Cell. Mol. Anesth. (2016) 1: 135-6.
Spanou E, Kalisperati P, Pateras IS, Papalampros A,

Barbouti A, Tzioufas AG, Kotsinas A and Sougioultzis

S. Genetic Variability as a Regulator of TLR4 and

NOD Signaling in Response to Bacterial Driven DNA

Damage Response (DDR) and Inflammation: Focus on

the Gastrointestinal (GI) Tract.
Front. Genet. (2017)
8: 65.

Kalaitzoglou E, Griffin TM and Humphrey MB.

Innate Immune Responses and Osteoarthritis.
Rheumatol. Rep.
(2017) 19: 45.
Xing LZ, Li L and Zhang LJ. Can intravenous steroid

administration reduce postoperative pain scores

following total knee arthroplasty?: A meta-analysis.

Medicine (Baltimore)
. (2017) 96: e7134.
Zhou DM, Zhuang Y, Chen WJ, Li W and Miao

B. Effects of Duloxetine on the Toll-Like Receptor

4 Signaling Pathway in Spinal Dorsal Horn in a

Rat Model of Diabetic Neuropathic Pain.
Pain. Med.
(2018) 19: 580-8.

Sepehri Z, Kiani Z, Kohan F, Alavian SM and Ghavami

S. Toll like receptor 4 and hepatocellular carcinoma; A

systematic review.
Life. Sci. (2017) 179: 80-7.
Trott O and Olson AJ. AutoDock Vina: improving the

speed and accuracy of docking with a new scoring

function, efficient optimization, and multithreading.
Comput. Chem
. (2010) 31: 455-61.
Davari K, Nowroozi J, Hosseini F, Sepahy AA and

Mirzaie S. Structure-based virtual screening to identify

the beta-lactamase CTX-M-9 inhibitors: An in silico

effort to overcome antibiotic resistance in
E. coli .
Comput. Biol. Chem
. (2017) 67: 174-81.
Kennedy MN, Mullen GE, Leifer CA, Lee C, Mazzoni

A, Dileepan KN and Segal DM. A complex of soluble

MD-2 and lipopolysaccharide serves as an activating

ligand for Toll-like receptor 4.
J. Biol. Chem. (2004)
279: 34698-704.

Hutchinson MR, Zhang Y, Brown K, Coats BD,

Shridhar M, Sholar PW, Patel SJ, Crysdale NY,

Harrison JA, Maier SF, Rice KC and Watkins LR.

Non-stereoselective reversal of neuropathic pain by

naloxone and naltrexone: involvement of toll-like

receptor 4 (TLR4).
Eur. J. Neurosci. (2008) 28: 20-9.
Svajger U, Brus B, Turk S, Sova M, Hodnik V,

Anderluh G and Gobec S. Novel toll-like receptor 4

(TLR4) antagonists identified by structure- and ligand-

based virtual screening.
Eur. J. Med. Chem. (2013)
70: 393-9.

Perez-Regidor L, Zarioh M, Ortega L and Martin-

Santamaria S. Virtual Screening Approaches towards

the Discovery of Toll-Like Receptor Modulators.
J. Mol. Sci
. (2016) 17(9).
Joce C, Stahl JA, Shridhar M, Hutchinson MR,

Watkins LR, Fedichev PO and Yin H. Application of

a novel in silico high-throughput screen to identify

selective inhibitors for protein-protein interactions.

Bioorg. Med. Chem. Lett
. (2010) 20: 5411-3.
Neal MD, Jia H, Eyer B, Good M, Guerriero CJ, Sodhi

CP, Afrazi A, Prindle T Jr, Ma C, Branca M, Ozolek

J, Brodsky JL, Wipf P and Hackam DJ. Discovery and

validation of a new class of small molecule Toll-like

receptor 4 (TLR4) inhibitors.
PLoS One (2013) 8:

























FDA Approved Drugs Repurposing of Toll-Like Receptor41647
Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P,

Pletneva LM, Karp CL, McAlees J, Gioannini TL,

Weiss J, Chen WH, Ernst RK, Rossignol DP, Gusovsky

F, Blanco JC and Vogel SN. The TLR4 antagonist

Eritoran protects mice from lethal influenza infection.

(2013) 497: 498-502.
Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE,

Kao R, Wheeler J, Gogate J, Opal SM; Eritoran Sepsis

Study Group. Phase 2 trial of eritoran tetrasodium

(E5564), a toll-like receptor 4 antagonist, in patients

with severe sepsis.
Crit. Care. Med. (2010) 38: 72-83.
Zhang S, Cheng K, Wang X and Yin H. Selection,

synthesis, and anti-inflammatory evaluation of the

arylidene malonate derivatives as TLR4 signaling




Bioorg. Med. Chem. (2012) 20: 6073-9.
Wang L, Zhang X, Liu L, Cui L, Yang R, Li M

and Du W. Tanshinone II A down-regulates HMGB1,

RAGE, TLR4, NF-kappaB expression, ameliorates

BBB permeability and endothelial cell function, and

protects rat brains against focal ischemia.
Brain. Res.
(2010) 1321: 143-51.

Qian B, Li F, Zhao LX, Dong YL, Gao YJ and

Zhang ZJ. Ligustilide Ameliorates Inflammatory Pain

and Inhibits TLR4 Upregulation in Spinal Astrocytes

Following Complete Freund′s Adjuvant Peripheral

Cell Mol. Neurobiol. (2016) 36: 143-9